Dicerna Pharmaceuticals (NASDAQ:DRNA) Earning Somewhat Positive Press Coverage, Study Shows

Headlines about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.1633505810774 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of analysts have recently commented on DRNA shares. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price objective for the company in a report on Monday, October 23rd. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target (up from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. Finally, SunTrust Banks started coverage on Dicerna Pharmaceuticals in a report on Monday, February 5th. They issued a “buy” rating and a $13.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. Dicerna Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $10.05.

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up $0.11 during trading hours on Wednesday, hitting $9.44. 128,900 shares of the company’s stock traded hands, compared to its average volume of 383,767. Dicerna Pharmaceuticals has a 12 month low of $2.52 and a 12 month high of $11.19. The firm has a market capitalization of $487.50, a price-to-earnings ratio of -2.75 and a beta of 2.75.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv bought 285,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Monday, December 18th. The stock was purchased at an average cost of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 29.41% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Dicerna Pharmaceuticals (NASDAQ:DRNA) Earning Somewhat Positive Press Coverage, Study Shows” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-dicerna-pharmaceuticals-drna-stock-price.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply